These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 25937367)

  • 1. Improving bioavailability and biodistribution of anti-HIV chemotherapy.
    Giacalone G; Hillaireau H; Fattal E
    Eur J Pharm Sci; 2015 Jul; 75():40-53. PubMed ID: 25937367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead.
    Sosnik A; Chiappetta DA; Carcaboso AM
    J Control Release; 2009 Aug; 138(1):2-15. PubMed ID: 19445981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming pharmacologic sanctuaries.
    Cory TJ; Schacker TW; Stevenson M; Fletcher CV
    Curr Opin HIV AIDS; 2013 May; 8(3):190-5. PubMed ID: 23454865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enabled clinical use of an HIV-1 attachment inhibitor through drug delivery.
    Timmins P; Brown J; Meanwell NA; Hanna GJ; Zhu L; Kadow JF
    Drug Discov Today; 2014 Sep; 19(9):1288-93. PubMed ID: 24727410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in oral drug delivery of antiretrovirals and the innovative strategies to overcome them.
    Sosnik A; Augustine R
    Adv Drug Deliv Rev; 2016 Aug; 103():105-120. PubMed ID: 26772138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomes as drug delivery system: a strategic approach for the treatment of HIV infection.
    Désormeaux A; Bergeron MG
    J Drug Target; 1998; 6(1):1-15. PubMed ID: 9769017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for improving patient adherence to therapy and long-term patient outcomes.
    Battaglioli-DeNero AM
    J Assoc Nurses AIDS Care; 2007; 18(1 Suppl):S17-22. PubMed ID: 17275718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Potential of Long-Acting, Tissue-Targeted Synthetic Nanotherapy for Delivery of Antiviral Therapy Against HIV Infection.
    Halling Folkmar Andersen A; Tolstrup M
    Viruses; 2020 Apr; 12(4):. PubMed ID: 32272815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs.
    Sharma P; Garg S
    Adv Drug Deliv Rev; 2010 Mar; 62(4-5):491-502. PubMed ID: 19931328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability [corrected].
    Chiappetta DA; Hocht C; Taira C; Sosnik A
    Nanomedicine (Lond); 2010 Jan; 5(1):11-23. PubMed ID: 20025460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
    Arab-Alameddine M; Lubomirov R; Fayet-Mello A; Aouri M; Rotger M; Buclin T; Widmer N; Gatri M; Ledergerber B; Rentsch K; Cavassini M; Panchaud A; Guidi M; Telenti A; Décosterd LA; Csajka C;
    J Antimicrob Chemother; 2014 Sep; 69(9):2489-98. PubMed ID: 24821595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-HIV efficacy and biodistribution of nucleoside reverse transcriptase inhibitors delivered as squalenoylated prodrug nanoassemblies.
    Hillaireau H; Dereuddre-Bosquet N; Skanji R; Bekkara-Aounallah F; Caron J; Lepêtre S; Argote S; Bauduin L; Yousfi R; Rogez-Kreuz C; Desmaële D; Rousseau B; Gref R; Andrieux K; Clayette P; Couvreur P
    Biomaterials; 2013 Jul; 34(20):4831-8. PubMed ID: 23562054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances of resveratrol in nanostructured based delivery systems and in the management of HIV/AIDS.
    Singh G; Pai RS
    J Control Release; 2014 Nov; 194():178-88. PubMed ID: 25217813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal drug treatment regimens for HIV depend on adherence.
    Krakovska O; Wahl LM
    J Theor Biol; 2007 Jun; 246(3):499-509. PubMed ID: 17320115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The recommendations of GESIDA/SEFH/PNS for improving adherence to antiretroviral treatment. AIDS Study Group of the Spanish Society of Hospital Pharmacy and the National Plan on AIDS of the Minister of Health and Consumers].
    Knobel H; Codina C; Miró JM; Carmona A; García B; Antela A; Gómez-Domingo MR; Arrizabalaga J; Iruin A; Laguna F; Jiménez I; Rubio R; Lluch A; Viciana P
    Enferm Infecc Microbiol Clin; 2000 Jan; 18(1):27-39. PubMed ID: 10721560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of formulation on the pharmacokinetics of antiretroviral drugs.
    Bastiaans DE; Cressey TR; Vromans H; Burger DM
    Expert Opin Drug Metab Toxicol; 2014 Jul; 10(7):1019-37. PubMed ID: 24877605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-sparing regimens for HIV combination therapy: benefits predicted for "drug coasting".
    Krakovska O; Wahl LM
    Bull Math Biol; 2007 Nov; 69(8):2627-47. PubMed ID: 17578648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.